Alexander Thompson

Jiale Song

Thomas Smith

Corinne Jenkins

Gavin Clark-Gartner

- Aclaris Therapeutics anticipates a **catalyst-rich 2026** with **four anticipated readouts** across its portfolio, including Phase 2 data for **Bosakatug (ATI-045)** in atopic dermatitis in the **second half of 2026**, and top-line data for the bispecific **ATI-052** in **early Q1 2026**, followed by two Phase 1b study readouts for ATI-052 by the **end of 2026**.  **[0001557746_2181100_1]** **[0001557746_2181100_2]** **[0001557746_2181100_21]** **[0001557746_2181100_22]** 
- The company's pipeline highlights include the bispecific **ATI-052**, which targets TSLP and IL4R and has demonstrated **four times greater potency** than the combination of dupilumab and tezepelumab in a PBMC assay, and an **ITK oral inhibitor franchise** with an IND for next-gen compounds anticipated in **2026**.  **[0001557746_2181100_1]** **[0001557746_2181100_14]** **[0001557746_2181100_18]** 
- Aclaris Therapeutics reports having a **capital runway through into the second half of 2028**.  **[0001557746_2181100_1]** **[0001557746_2181100_3]**

Aclaris Therapeutics Outlines 2026 Pipeline Catalysts and Financial Runway at R&D Day

- Aclaris Therapeutics projects its cash runway to extend into the **second half of 2028**, sufficient to fund its preclinical and clinical development plans.  **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:2]** 
- The company anticipates a **rich calendar of data events throughout 2026 and 2027**, with four potential clinical stage assets expected in **2026**.  **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:2]** **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:21]** 
- Key upcoming milestones include top-line results for **Bosakitug (ATI-045)** Phase 2 in atopic dermatitis in **2H 2026**  **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:18]** **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:20]** **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:21]** , and for **ATI-052**, top-line SAD/MAD results in **1Q 2026** and Proof-of-Concept results in asthma and AD in **2H 2026**.  **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:20]** **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:21]** 
- **ATI-2138**, an ITK/JAK3 inhibitor, demonstrated positive Phase 2a results in atopic dermatitis  **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:2]** **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:19]** , with Phase 2b initiation in a second indication (likely Lichen Planus) planned for **1H 2026** and top-line results in **2027**.  **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:20]** **[1557746_0001104659-25-098991_acrs-20251014xex99d1.htm:21]**

Aclaris Therapeutics Outlines Clinical Pipeline Progress and 2026 Milestones

- Aclaris Therapeutics, a clinical-stage biopharmaceutical company, expects multiple data readouts and catalysts in **2026** across its four key assets.  **[1557746_tx_379969_0]** 
- Key pipeline milestones include top-line data for its TSLP monoclonal antibody (ATI-405) in atopic dermatitis in **2026**, and bispecific (ATI-502) SADMAD data by the **end of 2025**, with two Phase Ib readouts in **2026**.  **[1557746_tx_379969_0]** 
- The company's oral ITK/JAK3 small molecule inhibitor (2138) will move into **alopecia areata later in 2025** following strong atopic dermatitis data.  **[1557746_tx_379969_0]** 
- Aclaris reported a cash balance of approximately **$181 million**, providing a cash runway through **mid-year 2028**, and is exploring monetizing its **IP royalty with Sun Pharma** in **2025** for non-dilutive financing.  **[1557746_tx_379969_7]**

Aclaris Therapeutics (ACRS)